Olezarsen – Medxy AI

Apolipoprotein C-III Inhibition and the Atherosclerosis Paradox: Lessons from the Essence-TIMI 73b Olezarsen Study

By MedXY 04/07/2026

The Essence-TIMI 73b trial reveals that despite a 64% reduction in triglycerides and a 72% drop in remnant cholesterol via olezarsen, non-calcified coronary plaque volume remained unchanged over 12 months.

Cardiology Gastroenterology news

Olezarsen Significantly Lowers Triglycerides and Cuts Pancreatitis Risk in Severe Hypertriglyceridemia: CORE‑TIMI 72a/CORE2‑TIMI 72b Results

By MedXY 11/10/2025

Two randomized trials found monthly olezarsen (50 mg and 80 mg) produced large, dose-dependent triglyceride reductions and a marked decrease in acute pancreatitis compared with placebo in patients with severe hypertriglyceridemia; higher doses were linked to liver enzyme elevations, thrombocytopenia, and increased hepatic fat.

Cardiology Clinical Updates news Specialties

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia: Advances in Antisense Therapies for Triglyceride Reduction

By MedXY 10/03/2025

Olezarsen, a GalNAc-conjugated antisense oligonucleotide targeting APOC3 mRNA, significantly reduces triglyceride levels in moderate hypertriglyceridemia, offering a promising therapeutic advance with favorable safety in cardiovascular risk patients.